Cigna Group’s (CI) “Outperform” Rating Reaffirmed at Royal Bank Of Canada

Cigna Group (NYSE:CI)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research report issued on Thursday, Benzinga reports. They currently have a $337.00 price objective on the health services provider’s stock. Royal Bank Of Canada’s target price points to a potential upside of 26.00% from the company’s current price.

CI has been the subject of several other reports. Raymond James Financial downgraded Cigna Group from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $350.00 to $320.00 in a research note on Monday, August 3rd. Wolfe Research reaffirmed an “outperform” rating and issued a $315.00 price objective on shares of Cigna Group in a research note on Tuesday, June 16th. Wells Fargo & Company raised their price objective on Cigna Group from $305.00 to $307.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Robert W. Baird set a $362.00 price target on Cigna Group in a research report on Friday, July 31st. Finally, Piper Sandler dropped their price target on Cigna Group from $370.00 to $346.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Cigna Group currently has an average rating of “Moderate Buy” and a consensus price target of $337.10.

Cigna Group Price Performance

NYSE CI traded down $4.38 during mid-day trading on Thursday, hitting $267.45. The stock had a trading volume of 1,014,203 shares, compared to its average volume of 1,679,360. Cigna Group has a 52-week low of $239.51 and a 52-week high of $315.47. The company has a market cap of $70.67 billion, a price-to-earnings ratio of 11.07, a P/E/G ratio of 0.93 and a beta of 0.31. The company has a 50 day simple moving average of $279.53 and a 200 day simple moving average of $280.55. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.68.

Cigna Group (NYSE:CI) last released its quarterly earnings data on Thursday, July 30th. The health services provider reported $7.78 earnings per share for the quarter, beating the consensus estimate of $7.60 by $0.18. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%.The firm had revenue of $71.56 billion during the quarter, compared to the consensus estimate of $70.14 billion. During the same period last year, the business posted $7.20 EPS. Cigna Group’s quarterly revenue was up 6.7% on a year-over-year basis. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Equities analysts forecast that Cigna Group will post 30.51 EPS for the current fiscal year.

Insider Buying and Selling at Cigna Group

In other news, insider Nicole S. Jones sold 2,677 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $279.61, for a total transaction of $748,515.97. Following the sale, the insider owned 25,880 shares in the company, valued at $7,236,306.80. This trade represents a 9.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $284.05, for a total value of $175,258.85. Following the sale, the insider owned 5,053 shares in the company, valued at $1,435,304.65. This trade represents a 10.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,730 shares of company stock worth $6,293,359 in the last 90 days. Insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Cigna Group

Several hedge funds have recently made changes to their positions in CI. GQG Partners LLC acquired a new position in Cigna Group in the second quarter valued at $1,628,918,000. Bank of America Corp DE acquired a new position in shares of Cigna Group during the second quarter worth about $827,692,000. Legal & General Group Plc acquired a new position in shares of Cigna Group during the second quarter worth about $542,779,000. Boston Partners lifted its stake in shares of Cigna Group by 314.6% during the fourth quarter. Boston Partners now owns 1,638,191 shares of the health services provider’s stock worth $450,856,000 after purchasing an additional 1,243,056 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Cigna Group during the second quarter worth about $241,312,000. Institutional investors and hedge funds own 86.99% of the company’s stock.

Key Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna introduced its “Lead to One” strategy, focusing on complex care, specialty pharmacy, affordability, personalization, data, technology and artificial intelligence. Management targets 10%–14% adjusted EPS compound annual growth through 2030, offering a potentially significant long-term earnings-growth catalyst. Cigna Investor Day announcement
• Positive Sentiment: The company plans to invest $3 billion in a multiyear modernization and productivity initiative. Although costly initially, Cigna expects the program to improve workflow, performance and operating efficiency. Increased investment in specialty pharmacy and complex care could also strengthen Evernorth’s competitive position. Cigna specialty pharmacy investment article
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and set a $337 price target, implying roughly 26% upside from the cited share price. A separate Seeking Alpha analysis characterized CI as undervalued and forecast double-digit EPS growth. Cigna valuation analysis
• Neutral Sentiment: Cigna reaffirmed its 2026 EPS guidance of approximately $30.45 and revenue guidance of $280 billion. The company also announced an exclusive agreement involving Cigna’s international health benefits business and UnitedHealthcare Global, potentially supporting its international platform, although the financial impact was not specified. Cigna international agreement
• Negative Sentiment: The 2026 revenue outlook of $280 billion is below the roughly $287.2 billion analyst consensus, while EPS guidance of $30.45 is slightly below the $30.51 consensus estimate. The $3 billion investment program may also create near-term expense and execution concerns, helping explain why the stock has decreased despite the favorable long-term targets. Cigna financial targets

Cigna Group Company Profile

The Cigna Group (NYSE: CI) is a global health company that provides health care and related services to individuals, employers, government organizations and health plans. Its operations are primarily organized through Cigna Healthcare and Evernorth Health Services, which together address health coverage, pharmacy services, care delivery and benefit management.

Cigna Healthcare offers medical, dental, behavioral health, disability and other benefits, with a focus on employer-sponsored and individual health plans in the United States as well as international health services.